A Promising All-Oral Regimen for HCV Infection Post–Liver Transplantation

Direct-acting antiviral agents (DAAs) have yielded high efficacy and improved tolerability and safety in treating hepatitis C virus (HCV) infection but have yet to be studied in patients with recurrent HCV infection after liver transplantation. The limited experience in treating this population with peginterferon with and without a DAA has demonstrated low efficacy and high rates of adverse events.

In a phase II, open-label trial, 34 posttransplantation patients with recurrent genotype 1 HCV infection with mild or no fibrosis received ombitasvir–ABT-450/r (NS5A inhibitor co-formulated with a ritonavir-boosted protease inhibitor; once daily) plus dasabuvir (nonnucleoside NS5B polymerase inhibitor; 250 mg twice daily) and ribavirin (400–1200 m…